TY - JOUR T1 - The HUNT Study: a population-based cohort for genetic research JF - medRxiv DO - 10.1101/2021.12.23.21268305 SP - 2021.12.23.21268305 AU - Ben M. Brumpton AU - Sarah Graham AU - Ida Surakka AU - Anne Heidi Skogholt AU - Mari Løset AU - Lars G. Fritsche AU - Brooke Wolford AU - Wei Zhou AU - Jonas Bille Nielsen AU - Oddgeir L. Holmen AU - Maiken E. Gabrielsen AU - Laurent Thomas AU - Laxmi Bhatta AU - Humaira Rasheed AU - He Zhang AU - Hyun Min Kang AU - Whitney Hornsby AU - Marta R. Moksnes AU - Eivind Coward AU - Mads Melbye AU - Guro F. Giskeødegård AU - Jørn Fenstad AU - Steinar Krokstad AU - Marit Næss AU - Arnulf Langhammer AU - Michael Boehnke AU - Gonçalo R. Abecasis AU - Bjørn Olav Åsvold AU - Kristian Hveem AU - Cristen J. Willer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/25/2021.12.23.21268305.abstract N2 - The Trøndelag Health Study (HUNT) is a population-based cohort of ∼229,000 individuals recruited in four waves beginning in 1984 in Trøndelag County, Norway. ∼88,000 of these individuals have available genetic data from array genotyping. HUNT participants were recruited during 4 community-based recruitment waves and provided information on health-related behaviors, self-reported diagnoses, family history of disease, and underwent physical examinations. Linkage via the Norwegian personal identification number integrates digitized health care information from doctor visits and national health registries including death, cancer and prescription registries. Genome-wide association studies of HUNT participants have provided insights into the mechanism of cardiovascular, metabolic, osteoporotic and liver-related diseases, among others. Unique features of this cohort that facilitate research include nearly 40 years of longitudinal follow-up in a motivated and well-educated population, family data, comprehensive phenotyping, and broad availability of DNA, RNA, urine, fecal, plasma, and serum samples.Competing Interest StatementG.R.A. works for Regeneron Pharmaceuticals. C.J.W.'s spouse works for Regeneron Pharmaceuticals. The remaining authors have no competing interests to declare.Funding StatementThe genotyping in HUNT was financed by the National Institutes of Health; University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. The genetic investigations of the HUNT Study is a collaboration between researchers from the K.G. Jebsen Center for Genetic Epidemiology, NTNU and the University of Michigan Medical School and the University of Michigan School of Public Health. The K.G. Jebsen Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norway.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The genotyping in HUNT and work presented in this cohort profile was approved by the Regional Committee for Ethics in Medical Research, Central Norway (2014/144, 2018/1622, 152023). All participants signed informed consent for participation and the use of data in research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearchers associated with Norwegian research institutes can apply for the use of HUNT data and samples with approval by the Regional Committee for Medical and Health Research Ethics. Researchers from other countries may apply if collaborating with a Norwegian Principal Investigator. Information for data access can be found at https://www.ntnu.edu/hunt/data. The HUNT variables are available for browsing on the HUNT databank at https://hunt-db.medisin.ntnu.no/hunt-db/. Data linkages between HUNT and health registries require that the principal investigator has obtained project-specific approval for such linkage from the Regional Committee for Medical and Health Research Ethics, Norway and each registry owner. https://www.ntnu.edu/hunt/data https://hunt-db.medisin.ntnu.no/hunt-db ER -